<DOC>
	<DOCNO>NCT00073125</DOCNO>
	<brief_summary>The primary objective study assess safety efficacy ABT-510 subject advance renal cell carcinoma .</brief_summary>
	<brief_title>Safety Efficacy ABT-510 Subjects With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>A subject eligible study participation follow criterion meet : The subject least 18 year age . The subject advance histologically document renal cell carcinoma . Advanced disease define locally recurrent disease metastatic disease amendable curative resection . The subject receive prior therapy ( antitumor radiotherapy , immunotherapy , chemotherapy , investigational therapy ) metastatic renal cell carcinoma excision primary tumor appropriate . Local radiation supportive reason allow ; however , within 28 day Study Day 1 . The subject Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 The subject able selfadminister caregiver reliably administer subcutaneous injection . The subject must adequate bone marrow , renal , hepatic function follow : Bone Marrow : White blood cell count ( WBC ) ≥ 3,000/mm3 ( 3.0 X 109/L ) ; Platelets ≥ 100,000/mm3 ( 100 X 109/L ) ; Hemoglobin ≥ 9.0 g/dL ( 1.4 mmol/L ) Renal function : serum creatinine ≤ 2.0 mg/dL ( 0.81 mmol/L ) Hepatic function : AST ALT ≤ 1.5 X ULN unless liver metastasis present , AST ALT ≤ 5.0 X ULN ; LDH ≤ 1.5 X ULN ; bilirubin ≤ 1.5 mg/dL ( 0.026 mmol/L ) Corrected calculated calcium ≤ 10 mg/dL ( 2.5 mmol/L ) Calculation = total calcium 0.707 ( albumin 3.4 ) Albumin ≥ 3.0 g/dL ( 0.45 mmol/L ) The subject must pregnant lactating subject ( male female ) must use contraceptive method deem acceptable investigator study two month follow completion therapy . The subject voluntarily sign date Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve consent prior study specific procedure . A subject ineligible study participation follow criterion meet : The subject history currently exhibit Central Nervous System ( CNS ) metastasis . Brain MRI within 28 day enrollment require confirm absence CNS metastases . The subject receive therapeutic anticoagulation therapy . Low dose anticoagulation ( e.g. , low dose Coumadin ) catheter prophylaxis permit ; PT/PTT must within normal limit . The subject history currently exhibit clinically significant cancer relate event bleed ( e.g. , hemoptysis ) . The subject recent history ( within 4 week Study Day 1 ) currently exhibit clinically significant sign bleed . The subject exhibit evidence clinically significant uncontrolled condition ( ) and/or consider investigator unable tolerate propose treatment procedure . The subject history previous malignancy within 5 year , exception : Adequately treat situ carcinoma cervix uteri Basal squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Advanced histologically document renal cell carcinoma</keyword>
</DOC>